演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

去勢抵抗性前立腺癌に対するアビラテロン、エンザルタミドの1年以上継続投与例の検討

演題番号 : P43-2

[筆頭演者]
演者)福森 知治:1 
[共同演者]
大豆本 圭:1、津田 恵:1、尾﨑 啓介:1、楠原 義人:1、森 英恭:1、布川 朋也:1、山本 恭代:1、山口 邦久:1、高橋 正幸:1、金山 博臣:1

1:徳島大学・泌尿器科

 

In order to predict long-term effect of androgen receptor-axis-targeted (ARAT) agents in patients with castration-resistant prostate cancer (CRPC), we retrospectively investigated the clinical characteristics of cases that was administered continuously with abiraterone acetate (AA) or enzalutamide (Enz) for at least one year.
A total of 71 consecutive patients with CRPC was treated with AA or Enz by October 2017, comprising 33 patients with AA alone, 26 patients in Enz alone, and 12 patients in both AA and Enz. Of 71 patients, consecutive 26 cases were administered with AA or Enz for at least one year, comprising 16 in AA alone and 10 in Enz alone.
The mean age was 75.9 years (range 62 to 85) in AA group and 76.3 years (range 67 to 84) in Enz group. The mean duration of administration was 24.7 months (range 14 to 34) in AA group and 22.9 months (range 12 to 36) in ENZ group. In the AA group, there were 14 cases with N0 (87.5%) and 11 cases (68.8%) in M0. In the Enz group, 6 cases (60%) in N0 and 4 cases (40.0%) in M0. Both in AA and Enz group, only 1 patient was preceded by docetaxel, and 5 patients (31.3%) in AA group and 1 patient (10.0%) in Enz group were preceded with other ARAT agents. The mean number of treatment regimens prior to ARAT agents were significantly less than that administered with AA or Enz within one year (2.7 vs 3.3, p=0.032 for AA group and 2.6 vs 3.5, p=0.015 for Enz group, respectively). Clinical efficacy in which PSA decreased by more than 50% or 90% was 10 cases (62.5%) and 5 cases (31.3%) in AA group, 8 cases (80.0%) and 4 cases (40.0%) in Enz group, respectively. Two patients (12.5%) in AA group were withdrawn from treatments for the reason of progression disease and 4 patients (40.0%) in Enz group for the reason of progression disease in 2 cases and adverse events in 2 cases.
These results suggest that the number of pre-ARAT-treatment regimens and clinical stage may affect the long-term ARTA administration in CRPC patients.

キーワード

臓器別:前立腺・男性生殖器

手法別:内分泌・ホルモン療法

前へ戻る